Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.
2.
3.

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.

J Clin Psychopharmacol. 2008 Oct;28(5):550-4. doi: 10.1097/JCP.0b013e318185e735.

PMID:
18794652
4.

Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.

Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A.

J Clin Psychiatry. 2005 Jan;66(1):73-9.

PMID:
15669891
5.
6.

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.

J Clin Psychiatry. 2005 Jun;66(6):736-43.

PMID:
15960567
7.

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.

Mohr N, Vythilingum B, Emsley RA, Stein DJ.

Int Clin Psychopharmacol. 2002 Jan;17(1):37-40.

PMID:
11800505
8.
9.

Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation.

Misri S, Milis L.

J Clin Psychopharmacol. 2004 Dec;24(6):624-7.

PMID:
15538124
10.

Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.

Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG.

J Clin Psychiatry. 2007 May;68(5):747-53.

PMID:
17503984
11.

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.

Atmaca M, Kuloglu M, Tezcan E, Gecici O.

Int Clin Psychopharmacol. 2002 May;17(3):115-9.

PMID:
11981352
12.

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.

Metin O, Yazici K, Tot S, Yazici AE.

Hum Psychopharmacol. 2003 Aug;18(6):463-7.

PMID:
12923825
13.

Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.

Sevincok L, Topuz A.

J Clin Psychopharmacol. 2003 Oct;23(5):448-50.

PMID:
14520120
14.

Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment.

Tenneij NH, van Megen HJ, Denys DA, Westenberg HG.

J Clin Psychiatry. 2005 Sep;66(9):1169-75.

PMID:
16187776
15.

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.

Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, Seedat S, Westenberg H, Denys D.

Int Clin Psychopharmacol. 2006 Nov;21(6):337-43.

PMID:
17012980
16.

Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.

Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB.

Int Clin Psychopharmacol. 2000 Sep;15(5):297-301.

PMID:
10993132
17.

Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.

Saxena S, Wang D, Bystritsky A, Baxter LR Jr.

J Clin Psychiatry. 1996 Jul;57(7):303-6.

PMID:
8666572
18.

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.

Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC.

J Psychopharmacol. 2010 Mar;24(3):297-307. doi: 10.1177/0269881108099423. Epub 2009 Jan 22.

PMID:
19164490
19.

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study.

Fineberg NA, Sivakumaran T, Roberts A, Gale T.

Int Clin Psychopharmacol. 2005 Jul;20(4):223-6.

PMID:
15933483
20.

Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.

Pallanti S, Quercioli L, Koran LM.

J Clin Psychiatry. 2002 Sep;63(9):796-801.

PMID:
12363120

Supplemental Content

Support Center